chenodeoxycholic acid leadiant (previously known as chenodeoxycholic acid sigma-tau)
leadiant gmbh - chenodeoxycholic happega - xanthomatosis, cerebrotendinous; metabolism, inborn errors - vere ja maksa ravi - chenodeoxycholic hape on näidustatud kaasasündinud vigadest esmane sapphapete sünteesi tõttu sterooli 27 hüdroksülaasi puudulikkus (esitades kui cerebrotendinous xanthomatosis (ctx)) imikutel, lastel ja noorukitel vanuses 1 kuu kuni 18 aastat ja täiskasvanute.
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.
lumigan
abbvie deutschland gmbh & co. kg - bimatoprost - glaucoma, open-angle; ocular hypertension - prostaglandin analogues, ophthalmologicals - suurenenud silmasisese rõhu langus kroonilise avatud nurga glaukoomi ja silma hüpertensioonina (monoteraapiana või beeta-adrenoblokaatorite täiendava ravina).
nobilis ib 4-91
intervet international bv - elus nõrgestatud lindude nakkav bronhiidi viiruse variant tüvi 4-91 - immunoloogilised ained - kana - kanade aktiivne immuniseerimine, et vähendada infektsioosse bronhiidi hingamisteede nähud, mida põhjustab varianti tüvi ib 4-91.
evusheld
astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.
evkeeza
ultragenyx germany gmbh - evinacumab - hüperkolesteroleemia - lipiidi modifitseerivad ained - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).
praxbind
boehringer ingelheim international gmbh - idarukisumab - hemorraagia - kõik muud ravitoimingud - praxbind on konkreetse pöördumise agent dabigatran ja on näidustatud täiskasvanud patsientidel, keda on ravitud pradaxa (dabigatran etexilate) kui kiire pöördumise oma antikoagulantide toimet, on vajalik:erakorralise kirurgia/kiireloomuliste kord;eluohtlikud või kontrollimatu verejooks,.
foster nexthaler inhalatsioonipulber
chiesi pharmaceuticals gmbh - formoterool+beklometasoon - inhalatsioonipulber - 6mcg+200mcg 1annus 120annus 2tk; 6mcg+200mcg 1annus 120annus 1tk
factor vii baxalta süstelahuse pulber ja lahusti
baxalta innovations gmbh - vii hüübimisfaktor - süstelahuse pulber ja lahusti - 600rÜ 1tk
haemate süste-/infusioonilahuse pulber ja lahusti
csl behring gmbh - von willebrandi faktor+viii hüübimisfaktor - süste-/infusioonilahuse pulber ja lahusti - 2400rÜ+1000rÜ 1tk